Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Saijo, Takeaki ^a,b,c   Maeda, Jun ^a   Okauchi, Takashi ^a   Maeda, Jun ichi ^c   Morio, Yasunori ^c   Kuwahara, Yasuhiro ^c   Suzuki, Masayuki ^c   Goto, Nobuharu ^c   Fukumura, Toshimitsu ^a   Suhara, Tetsuya ^a,b   Higuchi, Makoto ^a,b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3,4 DICHLOROPHENYL)PIPERIDIN 1 YL] 3 [2 (5 METHYL 1,3,4 OXADIAZOL 2 YL)BENZO[B]FURAN 4 YLOXY]PROPAN 2 OL; CARBON 11; DESIPRAMINE; FLUVOXAMINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE C 11; PINDOLOL; RADIOPHARMACEUTICAL AGENT; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SULFUR 35; UNCLASSIFIED DRUG; WF 516;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR INTERACTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; RAT; RECEPTOR OCCUPANCY;

ADMINISTRATION, ORAL; ANIMALS; AUTORADIOGRAPHY; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LIGANDS; MALE; OXADIAZOLES; PINDOLOL; PIPERAZINES; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SYNAPSES; TIME FACTORS;

RATTUS;

EID: 84864704043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042589     Document Type: Article

References (60)

1. Hamed A, Lee A, Ren XS, Miller DR, Cunningham F, et al. (2004) Use of antidepressant medications: are there differences in psychiatric visits among patient treatments in the Veterans Administration? Med Care 42: 551-559.
2. Hansen DG, Søndergaard J, Vach W, Gram LF, Rosholm JU, et al. (2003) Antidepressant drug use in general practice: inter-practice variation and association with practice characteristics. Eur J Clin Pharmacol 59: 143-149.
3. Uchida N, Chong MY, Tan CH, Nagai H, Tanaka M, et al. (2007) International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. Psychiatry Clin Neurosci 61: 522-528.
4. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, et al. (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326: 1014-1017.
5. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol Suppl 1: 19-26.
6. Adell A, Artigas F, (1991) Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 343: 237-244.
7. Invernizzi R, Belli S, Samanin R (1992) Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584, 322-324.
8. Chaput Y, de Montigny C, Blier P (1991) Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5, 219-229.
9. Hjorth S, Auerbach SB, (1994) Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 260: 251-255.
10. Celada P, Puig M, Amargós-Bosch M, Adell A, Artigas F, (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29: 252-265.
11. Artigas F, Romero L, de Montigny C, Blier P, (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378-383.
12. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F, (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349: 1594-1597.
13. Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, et al. (1997) How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 17: 446-450.
14. Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, et al. (1998) Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 18: 441-446.
15. Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, et al. (1996) Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur J Pharmacol 301: R5-7.
16. Martinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, et al. (2001) Differential occupancy of somatodendritic and postsynaptic 5-HT1A receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24: 209-229.
17. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, et al. (2000) Beta-blocker binding to human 5-HT1A receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology 23: 285-293.
18. Andrée B, Thorberg SO, Halldin C, Farde L, (1999) Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berlin) 144: 303-305.
19. Hirani E, Opacka-Juffry J, Gunn R, Khan I, Sharp T, et al. (2000) Pindolol occupancy of 5-HT1A receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635. Synapse 36: 330-341.
20. Corradetti R, Laaris N, Hanoun N, Laporte AM, Le Poul E, et al. (1998) Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br J Pharmcol 123: 449-462.
21. Maeda J, Morio Y, Oohashi Y, Katayama J, Nishiyama A, et al. (2006) Wf-516, a novel antidepressant with dual serotonergic activity: l. Receptorial and pharmacological profiles in comparison with reference antidepressants. European Neuropsychopharmacol 16: S333.
22. Papp M, Gruca P, Litwa E, Lason M, Przegalinski E, (2006) Antidepressant-like activity of Wf-516, an antagonist of 5-HT1A receptors and inhibitor of 5-HT reuptake, in a chronic mild stress model of depression in rat. Eur Neuropsychopharmacol 16: S305-S306.
23. El Mansari M, Blier P, (2008) In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus. Naunyn Schmiedebergs Arch Pharmacol 376: 351-361.
24. Saijo T, Maeda J, Okauchi T, Maeda J-i, Morio Y, et al. (2009) Utility of small animal positron emission tomographic imaging of rats for preclinical development of drugs acting on serotonin transporter. Int J Neuropsychopharmacol 12: 1021-1032.
25. McCarron JA, Turton DR, Pike VW, Polle KG, (1996) Remotely-controlled production of the 5-HT1A radioligand, [carbonyl-11C]WAY-100635, via 11C-carbokylation of an immobilized Grignard reagent. J Label Compd Radiopharm 38: 941-953.
26. Khawaja X, Evans N, Reilly Y, Ennis C, Minchin MC, (1995) Characterization of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J Neurochem 64: 2716-2726.
27. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, et al. (2005) Performance evaluation of the microPET focus: A third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46: 455-463.
28. Maeda J, Suhara T, Ogawa M, Okauchi T, Kawabe K, et al. (2001) In vivo binding properties of [carbonyl-11C]WAY-100635: effect of endogenous serotonin. Synapse 40: 122-129.
29. Takano A, Ito H, Arakawa R, Saijo T, Suhara T (2007) Effects of the reference tissue setting on the parametric image of 11C-WAY 100635. Nucl Med Commun 28, 193-198.
30. Serrats J, Artigas F, Mengod G, Cortés R, (2004) An autoradiographic study of the influence of pindolol upon [35S]GTPγS binding in rat, guinea pig and human brain. Int J Neuropsychopharmacol 7: 27-34.
31. Castro ME, Harrison PJ, Pazos A, Sharp T, (2000) Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT1A receptors in human and rat brain. J Neurochem 75: 755-762.
32. Kirby LG, Pernar L, Valentino RJ, Beck SG, (2003) Distinguishing characteristics of serotonin and non-serotonin-containing cells in the dorsal raphe nucleus: electrophysiological and immunohistochemical studies. Neuroscience 116: 669-683.
33. Andrade R, Nicoll RA, (1987) Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 394: 99-124.
34. Van den Hooff P, Galvan M, (1992) Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br J Pharmacol 106: 893-899.
35. Van den Hoof P, Galvan M, (1991) Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice. Eur J Pharmacol 196: 291-298.
36. Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, et al. (2004) Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29: 847-859.
37. Nakayama T, Suhara T, Okubo Y, Ichimiya T, Yasuno F, et al. (2002) In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response. Psychopharmacology (Berlin) 165: 37-42.
38. Rabiner EA, Gunn RN, Wilkins MR, Sargent PA, Mocaer E, et al. (2000) Drug action at the 5-HT1A receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635. Nucl Med Biol 27: 509-513.
39. Assie MB, Cosi C, Koek W, (1999) Correlation between low/high affinity ratios for 5-HT1A receptors and intrinsic activity. Eur J Pharmacol 386: 97-103.
40. Ng GY, George SR, Zastawny RL, Caron M, Bouvier M, et al. (1993) Human serotonin1B receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition. Biochemistry 32: 11727-11733.
41. Herndon JL, Glennon RA (1993) Serotonin receptors, agents, and actions. In: Kozikowsky A, editor. Drug design, molecular modeling, and the neurosciences. New York: Raven Press. Pp. 167-212.
42. Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, et al. (1999) High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem 72: 2127-2134.
43. Finnema SJ, Bang-Andersen B, Wikström HV, Halldin C, (2010) Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography. Curr Top Med Chem 10: 1477-1498.
44. Meller E, Goldstein M, Bohmaker K, (1990) Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol 37: 231-237.
45. Yocca FD, Iben L, Meller E, (1992) Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol Pharmacol 41: 1066-1072.
46. Milak MS, Severance AJ, Ogden RT, Prabhakaran J, Kumar JS, et al. (2008) Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med 49: 587-596.
47. Lemoine L, Verdurand M, Vacher B, Blanc E, Le Bars D, et al. (2010) [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur J Nucl Med Mol Imaging 37: 594-605.
48. Sprouse J, Braselton J, Reynolds L, (2000) 5-HT1A agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus. Biol Psychiatry 47: 1050-1055.
49. Sánchez C, Arnt J, Moltzen E, (1996) Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models. Eur J Pharmacol 315: 245-254.
50. Komori T, Shimoishi K, Harashima H, Otagiri M, (1998) Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. Biol Pharm Bull 21: 1376-1378.
51. Gugler R, Herold W, Dengler HJ, (1974) Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol 7: 17-24.
52. Duman RS, Malberg J, Nakagawa S, (2001) Regulation of adult neurogenesis by psychotropic drugs and stress. J Pharmacol Exp Ther 299: 401-407.
53. Radley JJ, Jacobs BL, (2002) 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res 955: 264-267.
54. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS, (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154: 37-43.
55. McAskill R, Mir S, Taylor D, (1998) Pindolol augmentation of antidepressant therapy. Br J Psychiatry 173: 203-208.
56. Seeman P, (2012) Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse 66: 88-93.
57. Dawson LA, Watson JM, (2009) Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 15: 107-117.
58. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, et al. (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510: 49-57.
59. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, et al. (2009) Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70: 326-333.
60. Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, et al. (2011) Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 72: 1166-1173.